LabStyle Innovations Announces Partnership With Leading Global Nutrition Data Source For Its Dario Blood Glucose Monitoring Device
Dario’s Diabetes Management Solution Now Incorporates Regionally Localized Food Database to Better Manage Sugar Levels
CAESAREA, Israel, April 9, 2014 /PRNewswire/ — LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced a partnership with the world’s leading global nutrition data application, FatSecret.
The FatSecret platform is being integrated with Dario’s powerful diabetes management software application to deliver localized nutrition datasets of generic foods, branded products and restaurant items, to empower people with diabetes to more easily track and manage their food intake and resulting blood sugar and insulin levels.
Dario(TM) users in LabStyle’s initial market locations in the United Kingdom, Italy and New Zealand will have these benefits immediately, and LabStyle looks forward to helping people thrive with diabetes as Dario(TM) reaches more locations in Europe this year and, pending regulatory approvals, in North America later in 2014.
With FatSecret, Dario(TM) is the only diabetes management app with a regionally localized food database, and the only tool that helps people with diabetes automatically log their sugars from a range of foods in all languages and countries around the world. FatSecret provides nutritional information such as carbohydrate and fat content on a broad range of food types, and such information when combined with Dario’s tools is expected to be very useful in showing users how foods consumed affect the individual’s diabetes.
“FatSecret is delighted to partner with Dario(TM) to seamlessly integrate the world’s best food and nutrition tools into Dario(TM), empowering people to take charge of their health and better manage their diabetes,” said Mr. Lenny Moses, co-founder of FatSecret.
“Logging and managing blood sugar levels is a critical activity to manage diabetes and calculate required insulin treatment, and is a daily challenge for people with diabetes,” explained Erez Raphael, President and Chief Executive Officer of LabStyle. “We are excited to partner with FatSecret to add their extensive food information database to our offering, providing access to critical food information for our users and making it easier for people to manage their diabetes.”
Erez continued, “We are seeking to make Dario(TM) the most comprehensive and value-added diabetes management solution available, and the feedback on Dario(TM) from our initial rollout has been very promising.”
With FatSecret, travelling with diabetes is much easier. Carbohydrate and fat content in even the most basic local foods like bread, coffee and restaurant meals vary around the world. With Dario(TM), people with Diabetes know how local foods they’re not familiar with impact their sugar levels, and what to do next.
Dario(TM) users simply log their blood sugar level recorded with their small and stylish Dario(TM) glucose meter and plug it directly into their smartphone. Users of other glucose meters can also manually insert their blood sugar levels recorded with their existing devices. Following simple prompts, users note the foods they’ve eaten from the FatSecret library, as well as recent physical activity and their mood or stress levels. Dario(TM) automatically logs this data to help people with diabetes know why their sugars change and better manage their condition with the right treatment.
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle’s flagship product is the Dario((TM)) personalized smart meter. Dario((TM)) received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario(TM) smart meter (Dario((TM)) Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: www.mydario.com and http://mydario.investorroom.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the “Company”) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the results of the integration of the FatSecret and Dario platforms as described herein as well as market acceptance of and the Company’s regulatory plans for Dario generally) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Contacts: Brenda Zeitlin Investor Relations Press Booke and Company, Inc. LabStyle Innovations +1-212-490-9095 email@example.com firstname.lastname@example.org
SOURCE LabStyle Innovations Corp.